Glucokinase Activators Modulate Insulin Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents are inadequate for effectively treating hyperglycemia and diabetes, as they do not adequately target glucokinase, a crucial enzyme for glucose homeostasis, leading to suboptimal insulin secretion and glycogen regulation.
Innovation Solution
Development of glucokinase activators, which are compounds that enhance the activity of glucokinase, increasing glucose metabolism in pancreatic β-cells and hepatocytes, thereby promoting insulin secretion and glycogen deposition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic agents are used to treat hyperglycemia and diabetes, then treatment is provided, but glucose metabolism is not adequately improved and insulin secretion is insufficient
Solution Approach 1:
The patent modifies the molecular structure of glucokinase activators by changing chemical parameters (formulae I and II with specific substituents R1-R6, n values, and stereochemistry) to optimize binding affinity and enzymatic activity, thereby improving insulin secretion and glucose metabolism effectiveness
Solution Approach 2:
The invention combines multiple structural components (bicyclic ring systems, heteroaryl groups, amide linkages, and specific substituents) into composite molecular structures that work synergistically to enhance glucokinase activation and improve therapeutic efficacy
2Productivity
If glucokinase activity is increased to improve glucose metabolism, then insulin secretion increases, but potential side effects and safety concerns arise
Solution Approach 1:
The patent introduces specific local structural features (chiral centers, specific heteroaryl substitutions, and stereospecific configurations) that locally optimize the interaction with glucokinase to enhance insulin secretion while minimizing off-target effects and improving safety profile
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The glucokinase activators increase insulin secretion and improve glucose metabolism, providing a potential therapeutic solution for hyperglycemia and diabetes by modulating glucokinase activity, thus addressing the limitations of existing treatments.
Implementation Method 1
Glucokinase (GK, Hexokinase IV) is one of four hexokinases that are found in mammals. The hexokinases catalyze the first step in the metabolism of glucose, i.e., the conversion of glucose to glucose-6-phosphate.
Implementation Method 2
GK is a rate-controlling enzyme for glucose metabolism in these two cell types. Compounds that activate GK and, thereby, increase the sensitivity of the GK sensor system are expected to be useful in the treatment of the hyperglycemia characteristic of all type II diabetes.
Data Source
AI summary
Compounds are provided for use with hexokinases that comprise: Formula(I) wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.